Company intelligence / Profile preview

Macada

Rehovot, Israel

Ownership: Private
Employees: ~450
Development stage: Other

Overview

Kamada has a portfolio of 6 FDA-approved commercial plasma-derived products addressing unmet needs in orphan and infectious diseases, with ongoing Phase 3 development for inhaled AAT in AATD.[1][2][3][4]

Therapeutic areas: HematologyImmunologyOtherInfectious DiseasesRare Diseases
Modalities: Plasma-derived proteinImmunoglobulinHyperimmune globulin
Industry: Biotech

Partnerships

Kedrion BiopharmaShire (now Takeda)Pfizer (distribution of Cibinqo in Israel)

Beyond the preview

Go deeper on Macada.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Macada.

Explore the full profile